• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

by Elizabeth | Jan 15, 2025 | News

Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to assess all strategic options for the Company Sustained volume of PPU...
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Announces its 2025 Financial Calendar

by Elizabeth | Jan 14, 2025 | News

Paris and Boston, January 14, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)platform, today announces the publication of its 2025...
Raising Pancreatic Cancer Awareness Through Patient Voices 

Raising Pancreatic Cancer Awareness Through Patient Voices 

by Elizabeth | Nov 26, 2024 | News

 With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer  Paris and Boston, November 26, 2024 – 5:45 p.m. CET – This Pancreatic Cancer Awareness Month, Mauna Kea Technologies...
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

by Elizabeth | Nov 20, 2024 | News

Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased to announce that Dr. Carlos...
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

Mauna Kea Technologies Announces Review of Strategic Alternatives 

by Elizabeth | Nov 19, 2024 | News

Paris and Boston, November 19, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that its Board of Directors,...
« Older Entries
Next Entries »

Articles récents

  • ‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center
  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}